PX1 Research Makes Retatrutide and BPC-157 Batch COAs Publicly Accessible Without a Purchase
Irvine, United States - September 25, 2026 / PX1 Research /
PX1 Research has made batch-specific Certificates of Analysis (COAs) publicly accessible for all of its domestically manufactured peptide compounds, including Retatrutide and BPC-157, as part of a structured approach to verifiable analytical documentation for in vitro and laboratory research applications. The move gives researchers direct access to compound-level data generated through a 7-stage analytical testing protocol applied to every batch produced at its cGMP-certified US peptide manufacturing facility.
Seven-Stage Testing Protocol Applied to Every Batch
PX1 Research applies a multi-step analytical process to each production batch prior to distribution. The protocol includes High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry, two methodologies widely used in pharmaceutical and biochemical research to assess compound identity, purity, and structural integrity. Results across all tested batches confirm purity levels at or above 99%, a threshold relevant to the precision demands of laboratory research environments.
The 7-stage structure is designed to address multiple variables that can affect compound quality, including structural confirmation, solvent residue levels, and potential contaminants. Each stage generates data that contributes to the final batch-specific COA, which is then made available for independent review. Researchers sourcing high-purity research peptides for in vitro studies can cross-reference COA data directly against their own experimental requirements before placing an order.
Domestic cGMP-Certified Manufacturing and Laboratory Testing Standards
PX1 Research conducts its production operations within US-based cGMP-certified facilities, meaning manufacturing processes conform to current Good Manufacturing Practice standards as they apply to research compound production. This domestic structure supports consistency in supply logistics, with distribution available to research institutions and laboratories across the country.
The company's adherence to laboratory testing standards that incorporate both HPLC and Mass Spectrometry places its analytical documentation in alignment with the verification methods commonly cited in peer-reviewed biochemical research. For laboratory researchers working with peptides such as Retatrutide - a compound studied in metabolic pathway research - and BPC-157, which appears in connective tissue and cellular research contexts, access to batch-level analytical data functions as a practical necessity rather than an optional supplement.
All compounds produced by PX1 Research are intended strictly for in vitro and laboratory research purposes. No products are formulated, labeled, or distributed for human consumption, and the COA documentation framework is oriented toward supporting research verification workflows rather than clinical or therapeutic applications.
Accessible COA Documentation Supports Research Verification
The decision to make COAs publicly accessible - rather than available only upon request - reflects a structural approach to research transparency. Laboratories evaluating sourcing options can review batch-specific documentation for compounds including Retatrutide and BPC-157 without initiating a purchase, allowing analytical data to inform procurement decisions ahead of any transaction.
PX1 Research has maintained its US peptide manufacturing operations with this testing infrastructure since 2019, applying the 7-stage protocol consistently across its compound catalog. The public availability of COA records extends that consistency into the documentation layer, creating an auditable record for each batch that enters distribution. For research teams operating under institutional protocols that require third-party purity verification, this format of documentation provides data that can be incorporated directly into pre-experimental review processes.
The compounds covered under the publicly accessible COA system span the full range of high-purity research peptides in PX1 Research's catalog, with Retatrutide and BPC-157 among those for which batch documentation is currently available for laboratory review.
About PX1 Research
PX1 Research is a US-based manufacturer of research peptides, operating cGMP-certified domestic production facilities and applying a 7-stage analytical testing process - including HPLC and Mass Spectrometry - to verify purity at or above 99% for all batch outputs. The company produces compounds for in vitro and laboratory research applications, with batch-specific Certificates of Analysis accessible to researchers for independent verification. PX1 Research has maintained domestic manufacturing operations since 2019.
Learn more at PX1 Research
Contact Information:
PX1 Research
100 Spectrum Center Dr, Suite 900
Irvine, CA 92618
United States
Cody Robert
+1 (949) 739-5700
https://px1research.com
